Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: A systematic review of the literature

European Urology

Volumn 67, Issue 5, 2015, Pages 852-863

  Ost, Piet ^a   Bossi, Alberto ^b   Decaestecker, Karel ^a   De Meerleer, Gert ^a   Giannarini, Gianluca ^c   Karnes, R Jeffrey ^d   Roach, Mack ^e   Briganti, Alberto ^f  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF UDINE   (Italy)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Lymph node excision; Neoplasm metastasis; Neoplasm recurrence; Prostatic neoplasms; Radiosurgery

Indexed keywords

CHOLINE; FLUORODEOXYGLUCOSE;

AORTA BIFURCATION; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; FEVER; GLEASON SCORE; HORMONAL THERAPY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENOPATHY; LYMPHOCELE; LYMPHORRHEA; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMATIC REVIEW;

EID: 84964267911     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.09.004     Document Type: Review

References (49)

1. M. Han, A.W. Partin, C.R. Pound, J.I. Epstein, and P.C. Walsh Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience Urol Clin North Am 28 2001 555 565
2. S. Joniau, A. Briganti, and P. Gontero Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study Eur Urol 67 2015 157 164
3. M. Bolla, H. van Poppel, and B. Tombal Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) Lancet 380 2012 2018 2027
4. P.L. Palmbos, and M. Hussain Non-castrate metastatic prostate cancer: have the treatment options changed? Semin Oncol 40 2013 337 346
5. A. Heidenreich, P.J. Bastian, and J. Bellmunt EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 65 2014 467 479
6. P.A. Abrahamsson Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature Eur Urol 57 2010 49 59
7. L.G. Taylor, S.E. Canfield, and X.L. Du Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer Cancer 115 2009 2388 2399
8. M. Garcia-Yuste, S. Cassivi, and C. Paleru The number of pulmonary metastases: influence on practice and outcome J Thorac Oncol 5 2010 S161 S163
9. L. Spelt, B. Andersson, J. Nilsson, and R. Andersson Prognostic models for outcome following liver resection for colorectal cancer metastases: a systematic review Eur J Surg Oncol 38 2012 16 24
10. S. Salah, K. Watanabe, and S. Welter Colorectal cancer pulmonary oligometastases: pooled analysis and construction of a clinical lung metastasectomy prognostic model Ann Oncol 23 2012 2649 2655
11. A. Ashworth, G. Rodrigues, G. Boldt, and D. Palma Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature Lung Cancer 82 2013 197 203
12. A.C. Tree, V.S. Khoo, and R.A. Eeles Stereotactic body radiotherapy for oligometastases Lancet Oncol 14 2013 e28 e37
13. M.T. Schweizer, X.C. Zhou, and H. Wang Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy Ann Oncol 24 2013 2881 2886
14. P. Ost, K. Decaestecker, and B. Lambert Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer Prostate 74 2014 297 305
15. R.R. Weichselbaum, and S. Hellman Oligometastases revisited Nat Rev Clin Oncol 8 2011 378 382
16. T. Treasure, M. Milosevic, F. Fiorentino, and F. Macbeth Pulmonary metastasectomy: what is the practice and where is the evidence for effectiveness? Thorax 69 2014 946 949
17. O.J. Garden, M. Rees, and G.J. Poston Guidelines for resection of colorectal cancer liver metastases Gut 55 Suppl 3 2006 iii1 iii8
18. D.Y. Kim, J.A. Karam, and C.G. Wood Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy World J Urol 32 2014 631 642
19. H. Jadvar Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline J Nucl Med 52 2011 81 89
20. V. Pasoglou, A. Larbi, and L. Collette One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified "all-in-one" imaging approach? Prostate 74 2013 469 477
21. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, and P. Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med 6 2009 e1000097
22. Moga C, Guo B, Schopflocher D, Harstall C. Development of a quality appraisal tool for case series studies using a modified Delphi technique. Institute of Health Economics Web site. http://www.ihe.ca/documents/Case%20series%20studies%20using%20a%20modified%20Delphi%20technique.pdf.
23. F. Casamassima, L. Masi, and C. Menichelli Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients Tumori 97 2011 49 55
24. A. Muacevic, M. Kufeld, C. Rist, B. Wowra, C. Stief, and M. Staehler Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer Urol Oncol 31 2011 455 460
25. F. Würschmidt, C. Petersen, A. Wahl, J. Dahle, and M. Kretschmer [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes Radiat Oncol 6 2011 44
26. K.A. Ahmed, B.M. Barney, B.J. Davis, S.S. Park, E.D. Kwon, and K.R. Olivier Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer Front Oncol 2 2012 215
27. B.A. Jereczek-Fossa, and G. Beltramo Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer Int J Radiat Oncol Biol Phys 82 2012 889 897
28. U. Schick, S. Jorcano, and P. Nouet Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases Acta Oncol 52 2013 1622 1628
29. K. Decaestecker, G. De Meerleer, and B. Lambert Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence Radiat Oncol 9 2014 135
30. M. Picchio, G. Berardi, and A. Fodor (11)C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients Eur J Nucl Med Mol Imaging 41 2014 1270 1279
31. L. Rinnab, F.M. Mottaghy, and J. Simon [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study Urol Int 81 2008 191 197
32. D. Schilling, H.P. Schlemmer, and P.H. Wagner Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer BJU Int 102 2008 446 451
33. A. Winter, J. Uphoff, R.P. Henke, and F. Wawroschek First results of [11C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy Urol Int 84 2010 418 423
34. C.A. Jilg, H.C. Rischke, and S.N. Reske Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer J Urol 188 2012 2190 2197
35. T. Martini, R. Mayr, and E. Trenti The role of C-choline-PET/CT-guided secondary lymphadenectomy in patients with PSA failure after radical prostatectomy: lessons learned from eight cases Adv Urol 2012 2012 601572
36. N. Suardi, G. Gandaglia, and A. Gallina Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years Eur Urol 67 2015 299 309
37. J. Busch, S. Hinz, and C. Kempkensteffen Selective lymph node dissection for castration-resistant prostate cancer Urol Int 88 2012 441 446
38. A. Trotti, A.D. Colevas, and A. Setser CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 2003 176 181
39. J.D. Cox, J. Stetz, and T.F. Pajak Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 31 1995 1341 1346
40. D. Dindo, N. Demartines, and P.A. Clavien Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey Ann Surg 240 2004 205 213
41. M. Durante, N. Reppingen, and K.D. Held Immunologically augmented cancer treatment using modern radiotherapy Trends Mol Med 19 2013 565 582
42. M.H. Umbehr, M. Müntener, T. Hany, T. Sulser, and L.M. Bachmann The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis Eur Urol 64 2013 106 117
43. M. Wondergem, F.M. van der Zant, T. van der Ploeg, and R.J. Knol A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer Nucl Med Commun 34 2013 935 945
44. D. Tilki, O. Reich, and A. Graser 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent Eur Urol 63 2013 792 796
45. N.M. Passoni, N. Suardi, and F. Abdollah Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series Urol Oncol 32 2014 38 e9-16
46. 11C-choline positron emission tomography/computerized tomography J Urol 192 2014 103 111
47. F. Abdollah, A. Briganti, and F. Montorsi Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy Eur Urol 67 2015 839 849
48. F.E. Lecouvet, J. El Mouedden, and L. Collette Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62 2012 68 75
49. K.S. Corbin, S. Hellman, and R.R. Weichselbaum Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy J Clin Oncol 31 2013 1384 1390